TolerogenixX
Manufacturing · Germany · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Lautenschlagerstrasse 20, Stuttgart, Bad...Phone Number
+49 1707704595Website
www.tolerogenixx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About TolerogenixX
TolerogenixX is a biopharmaceutical company specializing in the development of personalized therapies aimed at inducing immune tolerance in organ transplantation and autoimmune diseases. Their proprietary MIC (modified immune cells) technology offers a novel approach to modulate the immune system, potentially reducing the need for long-term immunosuppression. The company's lead product, MIC-Lx, has shown promising results in clinical trials for kidney transplant recipients, demonstrating sustained safety and effectiveness. TolerogenixX targets patients requiring organ transplants and those suffering from autoimmune conditions, aiming to improve their quality of life while minimizing side effects associated with traditional treatments.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TolerogenixX your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if TolerogenixX had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
TolerogenixX, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at TolerogenixX
Earning: See what the market has to say on TolerogenixX recently announced quarterly report
Product Launch: Get notified when TolerogenixX launches new products
Funding: Get notified immidiatlly once TolerogenixX has new funding data
Check if TolerogenixX has recently received funding, and reach out quickly before it becomes old news!
Check out if TolerogenixX is spiking on competitors!
Recommended Actions
Find VP level buyers at TolerogenixX
Find 2 more new buyers
Company Profile Activity
Activity Insights
TolerogenixX is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
TolerogenixX is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about TolerogenixX.
TolerogenixX Tech Stack
A closer look at the technologies used by TolerogenixX
See more technologies
TolerogenixX News & Media
TolerogenixX Completes Last Patient Transplant in Phase IIb TOL-2 Trial of MIC-Lx, Advancing a New Immune Tolerance Approach in Kidney Transplantation
Clinical Phase II milestone: All 63 donor-recipient pairs enrolled and treated according to protocol across multiple clinical centersEMA Grants PRIME Designation to TolerogenixX’s MIC-Lx Therapy for Donor-Specific Immune Tolerance in Kidney Transplantation
TolerogenixX´ MIC therapy receives EMA PRIME designation; up to 10-year follow‑up data support sustained safety and reduced immunosuppressionTolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
Heidelberg, July 6, 2023 – TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced that in the TOL2- Phase IIb study in renal transplant patients TolerogenixX has received green light by the Safety Board to initiate the B arm of the study. This arm consists of patients receiving minimal immune suppression drugs, reducing tacrolimus and weaning off entTolerogenixX Publishes Three-Year Follow-Up Data from Phase I Trial of Immune Tolerance-Inducing MIC-Lx Cell Therapy
Heidelberg, September 26, 2022 – TolerogenixX GmbH, a biopharmaceutical company developing personalized cellular therapies aimed at achieving sustained immune tolerance to combat organ rejection and autoimmune diseases, today announced 3-year follow-up data of a Phase I trial of its MIC-Lx cell therapy. The results published ahead of print in the Journal of the American Society of Nephrology (doi: 10.1681/ASN.2022020210) indicate that donor-specific immunosuppression after MIC infusion is long-l
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding TolerogenixX
Sign Up For FreeTo access detailed company insights
TolerogenixX is a biopharmaceutical company specializing in the development of personalized therapies aimed at inducing immune tolerance in organ transplantation and autoimmune diseases. Their proprietary MIC (modified immune cells) technology offers a novel approach to modulate the immune system, potentially reducing the need for long-term immunos... Read More
